/
We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.
Margins and capital returns are both well above average: 42.63% operating margin, ROIC at 38.98%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 64.1% YoY with margins expanding 29.1pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$300M
▲ +64.1% YoY
Net Income (TTM)
$364M
▲ +1999.1% YoY
Op. Margin
41.56%
▲ +29.1pp YoY
ROIC
32.46%
▲ +1.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$79M
▲ +140.4% YoY
Op. Cash Flow (TTM)
$79M
▲ +140.4% YoY
Net Debt
-$101M
Net Cash Position
Cash & Equiv.
$147M
5Y CAGR: +22.1%
Continue Research